If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 20.50
Bid: 20.00
Ask: 21.00
Change: -0.25 (-1.20%)
Spread: 1.00 (5.00%)
Open: 20.75
High: 20.75
Low: 20.50
Prev. Close: 20.75
IOF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing

12 Feb 2009 16:44

RNS Number : 2541N
Iofina PLC
12 February 2009
 



Iofina plc

Placing of £5 million

12 February 2009

The Directors of Iofina plc ("Iofina" or the "Company"), the gas and iodine production and development company, are pleased to announce that the Company has conditionally raised £5 million (before expenses) through a placing of 9,090,000 new ordinary shares of 1p each in the Company (the "Placing Shares"), at a price of 55p per share (the "Placing"). 

The net proceeds of the Placing will be primarily applied to pursue several new opportunities in the iodine derivatives market that have recently emerged. If entered into, the Directors believe the ensuing vertical integration through both production and derivatives should result in significantly better margins.

The Placing Shares will be subscribed for by certain new and existing institutional shareholders of the Company. The Placing is conditional, inter alia, on admission of the Placing Shares to trading on AIM ("Admission").

The Placing Shares will represent 8.83 per cent. of the then enlarged issued share capital of the Company immediately following Admission.  The number of ordinary shares of 1p each ("Ordinary Shares") in issue following the Placing, and the total number of voting rights, will be 102,906,114. The Placing Shares will rank pari passu with existing Ordinary Shares. Application will be made for Admission which is expected to take place on 18 February 2009.

David Schneider, Chief Executive, commented: "Despite extremely difficult capital market conditions, we have been delighted by the response of both new and existing institutional investors who share our excitement and vision with respect to vertically integrating Iofina into the iodine derivatives market The Placing was done at a 12% premium to the previous day's closing price.

With approximately £17m of net cash on the balance sheet on completion of the Placing, Iofina will be fully funded both to progress the Altantis prospect through to full development and positive cash flow generation, while at the same time move Iofina Chemical into the iodine derivatives market. This move will enhance Iofina's strategic position in the US where the large domestic blue chip end users of iodine derivatives currently rely heavily on imports from Chile and Japan. We continue to remain excited about Iofina's prospects and our ability to create value for our shareholders.

For further information, please contact: 

Lance Baller

Iofina plc

Tel: +44(0)20 3006 3135 x301

 

Nominated Adviser:

James Harris/Angela Peace

Strand Partners Limited

Tel: +44(0)20 7409 3494

 

Broker:

Rory Scott

Mirabaud Securities Limited

Tel: +44(0)20 7878 3360

 

Media Contact:

Chelsea Hayes

Pelham Public Relations

Tel: +44 (0)20 7743 6675

 

About Iofina

Iofina is involved in the exploration and production of both iodine and natural gas which have been discovered on acreages which the Company holds. The presence of both iodine and natural gas allows the Iofina group of companies (the "Group") to generate dual revenue streams over a single cost structure. The dual revenue approach has worked successfully in the Mobara field in Japan which has been producing iodine and natural gas for over the past 50 years. Iodine is a rare element that is only produced in a few countries in the world with over 79 per cent. coming from Chile (58 per cent.) and Japan (21 per cent.). This has resulted in the US and Western Europe becoming major net importers to meet growing demands from pharmaceutical and industrial manufacturers. Iodine demand is growing at 6.6 per cent. per annum driven by a combination of increased usage in a wide variety of sectors from pharmaceutical manufacturing, LCD screen manufacturing, medical imaging, cosmetics, biocides in paints and pesticides, as well as the emergence of new uses for iodine and greater consumption from developing countries such as India and China. The Group's proprietary Wellhead Extraction Technology® method will allow low cost production metrics and high operational efficiencies compared to other large iodine/gas fields in MobaraJapan and OklahomaUSA. Iofina owns a thirteen mile pipeline that ultimately links to the TransCanada pipeline. Iofina currently has leased over 60,000 net acres in the Atlantis Prospect and approximately 30,000 net acres in its Triton Prospect. MHA Petroleum Consultants, Inc., the Competent Person, estimates that as of 1 February 2008 and, based on Iofina's core c.28,000 acres at that time in the Atlantis Prospect, Iofina has 100.6 million kg of iodine in place and has 155.6Bcf of natural gas in place, making the Atlantis Prospect the largest known iodine resource in North America. The directors of the Company believe that Iofina's low cost development strategy and its dual revenue streams are expected to provide both excellent margins and reduced revenue volatility since the two product streams are unrelated relative to their respective markets.

Iofina is traded on the London Stock Exchange's AIM Market under the ticker: IOF. 

www.iofina.com 

Wellhead Extraction Technology® and WET® are registered trademarks of Iofina Natural Gas, Inc.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ROIDGGMZVZZGLZM
Date   Source Headline
2nd May 20247:00 amRNSFinal Results
16th Apr 20247:00 amRNSQ1 2024 Corporate Update
17th Jan 20247:00 amRNSHolding(s) in Company
15th Jan 20247:00 amRNSQ4 2023 Corporate Update
30th Nov 20237:00 amRNSIO#9 Update
20th Oct 20237:00 amRNSSigned Agreement for IO#10 and Q3 2023 Update
11th Sep 20237:00 amRNSInterim Results
25th Aug 20235:00 pmRNSHolding(s) in Company
24th Jul 20235:00 pmRNSHolding(s) in Company
20th Jul 20237:00 amRNSH1 Update and Updated Loan Facilities
14th Jun 20232:00 pmRNSResult of AGM
14th Jun 20237:00 amRNSIO#9 Iodine Plant Operating
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.